-DOCSTART- -X- O
The -X- _ O
persistent -X- _ O
public -X- _ O
health -X- _ O
threat -X- _ O
of -X- _ O
infection -X- _ O
with -X- _ O
Middle -X- _ O
East -X- _ O
respiratory -X- _ O
syndrome -X- _ O
coronavirus -X- _ O
( -X- _ O
MERS-CoV -X- _ O
) -X- _ O
highlights -X- _ O
the -X- _ O
need -X- _ O
for -X- _ O
an -X- _ O
effective -X- _ O
and -X- _ O
safe -X- _ O
MERS-CoV -X- _ O
vaccine. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
prepared -X- _ O
and -X- _ O
vaccinated -X- _ O
mice -X- _ B-Patient
with -X- _ O
either -X- _ O
a -X- _ O
Spike -X- _ B-Intervention
( -X- _ I-Intervention
S -X- _ I-Intervention
) -X- _ I-Intervention
protein -X- _ I-Intervention
or -X- _ O
inactivated -X- _ B-Intervention
whole -X- _ I-Intervention
MERS-CoV -X- _ I-Intervention
( -X- _ I-Intervention
IV -X- _ I-Intervention
) -X- _ I-Intervention
with -X- _ I-Intervention
a -X- _ I-Intervention
combined -X- _ I-Intervention
adjuvant -X- _ I-Intervention
( -X- _ I-Intervention
alum+CpG -X- _ I-Intervention
) -X- _ I-Intervention
as -X- _ O
a -X- _ O
vaccine -X- _ O
formulation. -X- _ O
Similar -X- _ B-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
anti-S -X- _ I-Outcome
protein -X- _ I-Outcome
IgG -X- _ I-Outcome
response -X- _ I-Outcome
and -X- _ I-Outcome
neutralizing -X- _ I-Outcome
activity -X- _ I-Outcome
were -X- _ I-Outcome
induced -X- _ I-Outcome
by -X- _ I-Outcome
both -X- _ I-Outcome
the -X- _ I-Outcome
S -X- _ I-Outcome
protein -X- _ I-Outcome
and -X- _ I-Outcome
IV -X- _ I-Outcome
vaccines. -X- _ I-Outcome
In -X- _ O
addition -X- _ O
, -X- _ O
immune -X- _ B-Outcome
responses -X- _ I-Outcome
against -X- _ I-Outcome
three -X- _ I-Outcome
other -X- _ I-Outcome
structural -X- _ I-Outcome
proteins -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
envelope -X- _ I-Outcome
( -X- _ I-Outcome
E -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
membrane -X- _ I-Outcome
( -X- _ I-Outcome
M -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
nucleocapsid -X- _ I-Outcome
( -X- _ I-Outcome
N -X- _ I-Outcome
) -X- _ I-Outcome
proteins -X- _ I-Outcome
, -X- _ I-Outcome
were -X- _ I-Outcome
also -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
sera -X- _ I-Outcome
of -X- _ I-Outcome
mice -X- _ I-Outcome
that -X- _ I-Outcome
received -X- _ I-Outcome
IV. -X- _ I-Outcome
No -X- _ I-Outcome
antigen-specific -X- _ I-Outcome
T-cell -X- _ I-Outcome
immunity -X- _ I-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
after -X- _ I-Outcome
vaccination -X- _ I-Outcome
based -X- _ I-Outcome
on -X- _ I-Outcome
the -X- _ I-Outcome
interferon-γ -X- _ I-Outcome
ELISpot -X- _ I-Outcome
assay. -X- _ I-Outcome
Mice -X- _ I-Outcome
were -X- _ I-Outcome
transduced -X- _ I-Outcome
with -X- _ I-Outcome
Ad5-hDPP4 -X- _ I-Outcome
after -X- _ I-Outcome
the -X- _ I-Outcome
final -X- _ I-Outcome
immunization -X- _ I-Outcome
and -X- _ I-Outcome
were -X- _ I-Outcome
then -X- _ I-Outcome
challenged -X- _ I-Outcome
with -X- _ I-Outcome
MERS-CoV -X- _ I-Outcome
( -X- _ I-Outcome
1 -X- _ I-Outcome
× -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
5 -X- _ I-Outcome
) -X- _ I-Outcome
plaque-forming -X- _ I-Outcome
units -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
Compared -X- _ O
with -X- _ O
the -X- _ O
control -X- _ B-Comparison
group -X- _ I-Comparison
( -X- _ I-Comparison
adjuvant -X- _ I-Comparison
alone -X- _ I-Comparison
) -X- _ I-Comparison
, -X- _ O
mice -X- _ B-Outcome
immunized -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
S -X- _ I-Outcome
protein -X- _ I-Outcome
or -X- _ I-Outcome
IV -X- _ I-Outcome
showed -X- _ I-Outcome
slightly -X- _ I-Outcome
lower -X- _ I-Outcome
pathological -X- _ I-Outcome
damage -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
lung -X- _ I-Outcome
, -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
reduced -X- _ I-Outcome
antigen -X- _ I-Outcome
expression -X- _ I-Outcome
and -X- _ I-Outcome
lung -X- _ I-Outcome
virus -X- _ I-Outcome
titers. -X- _ I-Outcome
Mice -X- _ I-Outcome
that -X- _ I-Outcome
received -X- _ I-Outcome
IV -X- _ I-Outcome
formulations -X- _ I-Outcome
also -X- _ I-Outcome
showed -X- _ I-Outcome
increased -X- _ I-Outcome
protective -X- _ I-Outcome
immunity -X- _ I-Outcome
( -X- _ I-Outcome
almost -X- _ I-Outcome
no -X- _ I-Outcome
live -X- _ I-Outcome
virus -X- _ I-Outcome
was -X- _ I-Outcome
isolated -X- _ I-Outcome
from -X- _ I-Outcome
the -X- _ I-Outcome
lung -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
In -X- _ O
conclusion -X- _ O
, -X- _ O
our -X- _ O
data -X- _ O
indicate -X- _ O
that -X- _ O
immunization -X- _ O
with -X- _ O
our -X- _ O
IV -X- _ O
formulation -X- _ O
induced -X- _ O
enhanced -X- _ O
protection -X- _ O
in -X- _ O
mice -X- _ O
compared -X- _ O
to -X- _ O
immunization -X- _ O
with -X- _ O
the -X- _ O
S -X- _ O
protein -X- _ O
against -X- _ O
MERS-CoV -X- _ O
, -X- _ O
which -X- _ O
should -X- _ O
be -X- _ O
further -X- _ O
tested -X- _ O
in -X- _ O
camels -X- _ O
and -X- _ O
clinical -X- _ O
trials -X- _ O
. -X- _ O

